Sat.Sep 05, 2020 - Fri.Sep 11, 2020

article thumbnail

New York Pharmacy Technician Requirements

Pharmacy Tech Scholar

New York Pharmacy Technician Requirements *Completing the PharmacyTechScholar.com Online Course and Passing the PTCE meets the proposed 2021 credentialing/training requirements in New York New York… The post New York Pharmacy Technician Requirements appeared first on PharmacyTechScholar.com.

PTCE 221
article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

Two UK biotechs – Destiny Pharma and Sporegen – have joined forces to develop a nasal spray that they say could serve as a first line of defense against coronavirus infections. The nasal spray could provide protection from infection within a few days of administration, and would be easy to make in bulk at a low cost, say the partners. The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the viru

Vaccines 133
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FSD Pharma announces Phase II trial for potential COVID-19 treatment

Outsourcing Pharma

The company has submitted an investigational new drug application for FSD201, a possible therapy for patients with severe cases of the virus.

126
126
article thumbnail

How Can Nursing Homes Protect Themselves from COVID-19?

Pharma Mirror

There is an ongoing pandemic that has been proven to harm and even kill many people. Researchers have found that the elderly are particularly susceptible to the COVID-19 virus that caused the epidemic. This is because they often have weaker immune systems, so they can’t fight off a viral infection easily. This new situation puts. The post How Can Nursing Homes Protect Themselves from COVID-19?

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Pre-Interview Tips for Pharmacy Professionals | Tip #2

indispensable health

Pre-Interview Tips for Pharmacy Professionals | Tip #2 with Tom Alig | Vice President of Staffing at Indispensable Health I am Tom Alig, VP of Staffing with Indispensable Health. I’ve been recruiting pharmacists and pharmacy technicians since 2004, and I’ve seen the things good candidates do to separate themselves, and I’ve seen the mistakes that some candidates make.

52
article thumbnail

Ex-Allergan CEO Saunders pops up again in ‘blank cheque’ company

pharmaphorum

Brent Saunders has been out of the limelight for a few months since departing Allergan after its takeover by AbbVie, but now he is back in a leading role at Vesper Healthcare Acquisition, set up to acquire assets in the healthcare sector. Delaware-incorporated Vesper has filed a with a $400 million initial public offering (IPO) and plans to list on the Nasdaq under the symbol VSRU, with Goldman Sachs and JP Morgan acting as bookrunners.

119
119

More Trending

article thumbnail

Cholestyramine and Warfarin – Not What You Might Think

Med Ed 101

When most healthcare professionals think about drug interactions, we tend to think about an issue arising when a medication is added to the regimen. A perfect example is the warfarin Bactrim interaction. Here’s a case scenario involving cholestyramine and warfarin that you might not necessarily think about. A 77-year-old female has a history of chronic […].

40
article thumbnail

NICE turns down Celgene's Revlimid as multiple myeloma maintenance treatment

Pharma Times

The drug's cost-effectiveness estimate when used in the maintenance setting is uncertain, the Institute has concluded

53
article thumbnail

Pharma ‘must not dodge liability for harm in COVID-19 vaccine trials’

pharmaphorum

An EU consumer body has urged the European Commission to keep compensation measures in place for people who might be harmed in COVID-19 vaccine trials, responding to reports that the drug industry is lobbying to reduce liability. In a letter to the Commissioner for Health and Food Safety Stella Kyriakides, the BEUC says that even though the need for a coronavirus vaccine is urgent, access “must go hand in hand with adequate consumer compensation in case of harm.”.

Vaccines 119
article thumbnail

Daxor research battles military injuries

Outsourcing Pharma

The company is delving into clinical research partnerships geared toward saving the lives of soldiers, eventually translating findings to civilian care.

97
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Sinemet 10/100 – Why You Shouldn’t Use It

Med Ed 101

Parkinson’s disease can be very debilitating and not understanding how medications should be dosed can compound the problem. Let’s review the pharmacology briefly and why you need to be careful with Sinemet 10/100. In Parkinson’s, we have a dopamine shortage. Levodopa is converted to dopamine in the brain but before it can get to the […].

article thumbnail

Pfizer, BioNTech could supply EU with 300m doses of SARS-CoV-2 vaccine

Pharma Times

The proposed deal covers the initial supply of 200 million doses and an option to purchase an additional 100 million, with deliveries starting by the end of 2020, if the vaccine is approved

article thumbnail

Digital success for pharma services in a uncertain world

pharmaphorum

Laura Morrill from ECI Partners looks at why data and technology are the keys to success in pharma services post-COVID. The pharmaceuticals industry has, for some time, been behind the curve when it comes to the adoption of technology. High barriers to entering the sector and high levels of regulation are just two factors that have meant that there has often been an “innovation lag” when it comes to implementing new technologies and embracing technological and digital change in the pharma indust

article thumbnail

Cynata Therapeutics kicks off COVID-19 trial enrollment

Outsourcing Pharma

The clinical-stage biotech firm is investigating early efficacy of its Cymerus mesenchymal stem cells for treatment of severe COVID-19 patients.

77
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Best Over the Counter Sleeping Pills UK

Druggist

Insomnia is a common sleep disorder, which is characterised by a difficulty in getting to sleep or maintaining the sleep (waking up at night or early in the morning). Sedative antihistamines can be used as a temporary aid to help with sleeping problems. In this post, I will review all over the counter sleeping pills (OTC) available in the UK. All of the non-prescription sleeping pills available in the UK contain sedative antihistamines.

article thumbnail

PharmaTimes 2020 competitions – there's still time to enter!

Pharma Times

2020's competitions will uphold the highly-respected judging criteria seen in previous years but with virtual processes enabling entrants to compete for a Pharma award from the comfort of their own homes

35
article thumbnail

How companies can encourage more diversity and inclusion in pharma

pharmaphorum

September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares with us his insights on why diversity and inclusion is so important and why it is critical to the future success of the life sciences sector. Taking diversity and inclusion seriously, supported by robust policies and accountability for implementation, creates success for everyone, fostering happy, healthy and invested employees, new ways of thinking and opportunities for growth, learning

110
110
article thumbnail

Medidata unveils centralized statistical monitoring

Outsourcing Pharma

The companyâs Medidata Detect centralized trial monitoring solution is designed to improve management of data quality, site monitoring and patient safety.

52
article thumbnail

Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response

pharmaphorum

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. Preliminary results published in The Lancet are from a non-randomised phase 1/2 trial of 76 people aged 18-60, which found an antibody response within 21 days and no serious adverse events after 42 days.

article thumbnail

AI could drive health systems in lower-income countries – report

pharmaphorum

Health systems in lower-income countries could overtake those in richer countries with AI-enabled technologies, according to a report from Novartis Foundation and Microsoft. Technologies such as mobile phone trading platforms, e-banking, e-commerce, and even blockchain applications have often been adopted more quickly and comprehensively in low- and middle-income countries than in high-income countries, the report found.

article thumbnail

Searching for answers in rare epilepsy

pharmaphorum

Geneticist Dr Charles Steward has spent his career studying the human genome – but his work became much more personal when his children were diagnosed with severe neurological diseases. Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate. For some people, a job is more than just a job.

Hospitals 100
article thumbnail

Unpleasant truth: the pandemic, record debt and our opportunity for sustainability

pharmaphorum

Sandoz’s Pierre Bourdage looks at the unexpected secondary impacts of COVID-19 on countries and healthcare systems, and asks how pharma can help improve sustainability to tackle them. It is undeniable that the COVID-19 pandemic has had a tremendous impact on all aspects of our lives, with ripple effects continuing to evolve. Faced with constant and overwhelming information about the pandemic, including rapidly changing policy responses, there is also an alarming acceleration of a healthcare sust

article thumbnail

Is a lack of real-time data holding trials back?

pharmaphorum

It’s 2020 and the digital revolution is well on its way. Yet, for clinical trials worldwide, real-time access to data is not the norm – and that lack can create a cascading set of issues affecting every aspect of a study. Critical decisions are too often being made in a digital data vacuum. At best, processes are not as efficient as they could be; at worst, serious problems may go undetected for weeks or even months.

article thumbnail

How companies can encourage more diversity and inclusion in pharma

pharmaphorum

September is Global Diversity and Inclusion month – David Peacock, managing director of MSD in the UK shares with us his insights on why diversity and inclusion is so important and why it is critical to the future success of the life sciences sector. Taking diversity and inclusion seriously, supported by robust policies and accountability for implementation, creates success for everyone, fostering happy, healthy and invested employees, new ways of thinking and opportunities for growth, learning

85
article thumbnail

Losing ground in COVID-19 vaccine race, CanSino turns to Russia

pharmaphorum

Politicking between China and Canada threatened to slow down development of a coronavirus vaccine from CanSino Biologics, but the company says the project is back on track following regulatory approval to start trials in Russia. The Chinese biotech’s adenovirus-based vaccine – developed in alliance with the military – was among the first to start clinical trials as the pandemic gathered pace earlier this year, but development timelines are slipping.

article thumbnail

Roche hits back at Novartis with new data for MS drug Ocrevus

pharmaphorum

Roche has hit back at Novartis’ newly-approved multiple sclerosis drug Kesimpta, with new data from its already-marketed blockbuster Ocrevus. Ocrevus (ocrelizumab) was approved in 2017 for relapsing and primary progressive forms of MS and is seen as one of the most successful drug launches in pharma history, generating sales of $3.79 billion in 2019 with more growth predicted this year.

article thumbnail

Searching for answers in rare epilepsy

pharmaphorum

Geneticist Dr Charles Steward has spent his career studying the human genome – but his work became much more personal when his children were diagnosed with severe neurological diseases. Charlie told pharmaphorum how his search for a genetic cause has led him to straddle the divide between scientist and patient advocate. For some people, a job is more than just a job.

article thumbnail

Debiopharm backs €10m funding for ‘digital sedation’ firm Oncomfort

pharmaphorum

A company that has developed a digital treatment for pain and anxiety – Belgium-based Oncomfort – has raised €10 million in first-round financing that will be used to fund international growth. Oncomfort has created a platform called Sedakit that provides ‘digital sedation’ – clinical hypnotherapy sessions delivered via a virtual reality headset accompanied by scripts and immersive sounds designed to dissociate patients from their symptoms.

80
article thumbnail

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cancer drug

pharmaphorum

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech. The US drugmaker is paying $200 million upfront for lemzoparlimab, which targets CD47 – an immune checkpoint on malignant cells that helps them evade being destroyed by immune cells such as macrophages. It has also pledged another $1.74 billion in payments due if the drug achieves development and sales objectives. $20 million of the upfront fee is tied

article thumbnail

AI could drive health system development in lower-income countries

pharmaphorum

Health systems in lower-income countries could overtake those in richer countries with artificial intelligence (AI)-enabled technologies, according to a report from Novartis Foundation and Microsoft. According to the report “Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity” , technologies such as mobile phone trading platforms, e-banking, e-commerce and blockchain applications have been adopted faster and more comprehensively in low- and middle-income countri

59
article thumbnail

Insmed trumpets mid-stage results from rare lung disease drug

pharmaphorum

US biotech Insmed has trumpeted updated phase 2 data from its brensocatib, at this week’s virtual European Respiratory Society conference, showing the drug prolonged time to exacerbations caused by the rare lung disease known as non-cystic fibrosis bronchiectasis (NCFBE). The results, also published in the New England Journal of Medicine, showed that brensocatib significantly prolonged time to first pulmonary exacerbation, the primary endpoint, over the 24-week treatment period for both treatmen

article thumbnail

After a nay from NICE, Scotland says aye to J&J’s Spravato

pharmaphorum

NHS patients with treatment-resistant depression in Scotland will be able to access Johnson & Johnson’s Spravato, a drug that has been turned down twice by NICE for patients in England. The Scottish Medicines Consortium – NICE’s equivalent north of the border – backed the use of Spravato (esketamine) nasal spray at its meeting this week, giving it the go-ahead for people with major depression who haven’t responded to at least two different antidepressants.

59
article thumbnail

AZ’s Fasenra on target in nasal polyps trial

pharmaphorum

AstraZeneca’s Fasenra (benralizumab) injected drug cuts the size of nasal polyps and nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company announced top-line results from the phase 3 OSTRO trial, which lasts for 56 weeks and compared Fasenra with placebo. Fasenra demonstrated a statistically significant improvement in the endoscopic total nasal polyp score and the nasal blockage score compared to placebo, in patients with severe disease who were still sym

52
article thumbnail

Merck & Co plans to file cough drug gefapixant after phase 3 success

pharmaphorum

Merck & Co is planning to file a drug for unexplained or treatment-resistant cough after supportive results from two phase 3 trials. US-based Merck , known as MSD outside the US and Canada, said results from the phase 3 COUGH-1 and COUGH-2 trials will form the basis of filings with regulators across the world. Data from the trials were revealed at this year’s virtual European Respiratory Society (ERS) International Congress.